SRT-3025 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1.

It has been investigated as a potential treatment for osteoporosis,[1][2][3][4][5] and anemia.

[6][7]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.